Study of 'Super Responder' Reveals New Oncogene for Lung Cancer

“Researchers have taken the next step in confirming the identity of previously unknown gene mutation that drives lung cancer development. Scientists at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) originally identified the mutation in one patient out of nine with advanced lung cancer who responded well to the drug sorafenib. The clinical trial involved 306 participants total.

“Within two months of beginning treatment, the patient had demonstrated a near complete response, and she remained progression-free and asymptomatic for five years while continuing to take sorafenib by mouth.”

Editor’s note: Different patients’ tumors have different genetic mutations. More and more, doctors are using patients’ tumor genetics to match patients with treatments that are most likely to work for them. Now, researchers have discovered a mutation called S214C, which may help doctors predict some lung cancer patients’ responses to treatment. The mutation was found in a patient in a clinical trial who responded particularly well to a drug called sorafenib.